Hereditary Cancer Program, Catalan Institute of Oncology - ICO, Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge - IDIBELL, Ciber Oncología (CIBERONC) - Instituto de Salud Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.
Pediatric Oncology Unit, Hospital Sant Joan de Déu, Esplugues, Barcelona, Spain.
J Med Genet. 2020 Apr;57(4):269-273. doi: 10.1136/jmedgenet-2019-106272. Epub 2019 Sep 7.
Lynch syndrome (LS) and constitutional mismatch repair deficiency (CMMRD) are hereditary cancer syndromes associated with mismatch repair (MMR) deficiency. Tumours show microsatellite instability (MSI), also reported at low levels in non-neoplastic tissues. Our aim was to evaluate the performance of high-sensitivity MSI (hs-MSI) assessment for the identification of LS and CMMRD in non-neoplastic tissues.
Blood DNA samples from 131 individuals were grouped into three cohorts: baseline (22 controls), training (11 CMMRD, 48 LS and 15 controls) and validation (18 CMMRD and 18 controls). Custom next generation sequencing panel and bioinformatics pipeline were used to detect insertions and deletions in microsatellite markers. An hs-MSI score was calculated representing the percentage of unstable markers.
The hs-MSI score was significantly higher in CMMRD blood samples when compared with controls in the training cohort (p<0.001). This finding was confirmed in the validation set, reaching 100% specificity and sensitivity. Higher hs-MSI scores were detected in biallelic carriers (n=5) compared with carriers (n=15). The hs-MSI analysis did not detect a difference between LS and control blood samples (p=0.564).
The hs-MSI approach is a valuable tool for CMMRD diagnosis, especially in suspected patients harbouring MMR variants of unknown significance or non-detected biallelic germline mutations.
林奇综合征(LS)和错配修复缺陷综合征(CMMRD)是与错配修复(MMR)缺陷相关的遗传性癌症综合征。肿瘤表现为微卫星不稳定(MSI),非肿瘤组织中也有低水平的报道。我们的目的是评估高灵敏度 MSI(hs-MSI)评估在非肿瘤组织中识别 LS 和 CMMRD 的性能。
从 131 个人的血液 DNA 样本中分为三个队列:基线(22 个对照)、训练(11 个 CMMRD、48 个 LS 和 15 个对照)和验证(18 个 CMMRD 和 18 个对照)。使用定制的下一代测序面板和生物信息学管道检测微卫星标记的插入和缺失。计算表示不稳定标记百分比的 hs-MSI 分数。
与训练队列中的对照相比,CMMRD 血液样本的 hs-MSI 评分显着更高(p<0.001)。在验证集中也证实了这一发现,达到了 100%的特异性和敏感性。在双等位基因携带者(n=5)中检测到更高的 hs-MSI 评分,而在杂合子携带者(n=15)中则较低。hs-MSI 分析未检测到 LS 和对照血液样本之间的差异(p=0.564)。
hs-MSI 方法是 CMMRD 诊断的有价值工具,特别是在怀疑存在 MMR 变异不明意义或未检测到双等位基因突变的疑似患者中。